A Breakthrough in MS Treatment

APH-1504 is a next-generation oral nanotherapeutic formulated with pure cannabidiol (CBD) to treat Multiple Sclerosis (MS)—a progressive, neurodegenerative disease of the central nervous system that affects over 2 million people globally. As one of the leading causes of long-term disability in young adults, MS demands safer, more effective therapies. APH-1504 is designed to meet this need.

Unlike Sativex®, which contains both CBD and psychotropic Δ9-THC, APH-1504 delivers non-psychotropic CBD in an aqueous-phase nanoencapsulation that improves drug absorption, enhances CNS penetration, and eliminates the alcohol and THC-related side effects found in earlier cannabinoid therapies.

Key Advantages of APH-1504

• ✅ Pure CBD, Non-Psychotropic – No THC, no intoxicating effects
• ✅ Oral Nanoformulation – Easy administration with improved bioavailability
• ✅ Enhanced Blood-Brain Barrier Penetration – Reaches target sites in the CNS
• ✅ No Alcohol, Better Tolerability – No sore mouth or irritation
• ✅ Biological Response Modifier – May delay or prevent MS progression
• ✅ FDA 505(b)(2) Pathway – Accelerated development and approval strategy

Addressing Unmet Needs in MS

MS is a highly variable disease that causes muscle weakness, fatigue, cognitive dysfunction, and eventually, severe neurological decline. Current therapies are often expensive, hard to administer, or palliative rather than disease-modifying. APH-1504 targets these limitations by:

• Enabling earlier, simpler treatment of MS flares
• Offering a safe, non-opioid alternative
• Reducing risk of progression to Secondary Progressive MS (SPMS)

Market Potential

The global market for MS therapeutics was valued at $16.6 billion in 2017, with sustained growth driven by innovations in drug delivery and neuroprotective agents. APH-1504 enters this market with unique advantages that position it as a disruptive, high-impact therapy.

Development Timeline

We are currently advancing APH-1504 through:

• ✅ Preclinical studies and scale-up
• 🔜 IND submission
• 🔜 Phase 1/2 and 3 clinical trials
• 🔜 NDA filing and commercial launch

Leveraging the FDA’s 505(b)(2) pathway, we aim to accelerate clinical development and reduce regulatory risk.

Contact Us

Interested in collaborating, investing, or learning more about APH-1504?📩 Email us at: info@aphios.com🌐 Visit: www.aphios.com